Olema Pharmaceuticals (OLMA) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Olema Pharmaceuticals (OLMA) over the past year, gaining 5.3% versus a loss of 26.8%. Over five years, ZVRA leads with a +16.6% price change compared with -74.5% for OLMA. Olema Pharmaceuticals is the larger company by market cap ($684.2 million vs $676.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OLMA | ZVRA |
|---|---|---|
| Share price | $7.82 | $11.39 |
| Market cap | $684.23M | $676.38M |
| 1-day change | 0.00% | +3.55% |
| YTD return | -68.72% | +27.12% |
| 1-year return | -26.78% | +5.27% |
| 5-year return | -74.54% | +16.58% |
| P/E ratio (TTM) | — | 12.38 |
| Forward P/E | — | 10.58 |
| EPS (TTM) | $-2.12 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.26 | $15.04 |
| 52-week low | $6.65 | $8.01 |
| Distance from 52-week high | -78.43% | -24.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +366.75% | +119.49% |
| Average volume | 1.06M | 1.09M |
| Shares outstanding | 87.50M | 59.38M |
| Employees | 150 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed OLMA by 32.0 percentage points over the past year.
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 150 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
OLMA vs ZVRA FAQ
Which is bigger, Olema Pharmaceuticals or Zevra Therapeutics?
Olema Pharmaceuticals (OLMA) is larger, with a market capitalization of $684.23M compared with $676.38M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, OLMA or ZVRA?
ZVRA returned +5.27% over the past 12 months, compared with -26.78% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Olema Pharmaceuticals and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.